Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

about

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

P2860

Q34675869-45F7CBE5-AB09-4E6F-9EF8-D6BFB88D9DAC Q42396417-BEF67D14-EFD3-44E5-82F8-3036953423AF

P2860

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Item

http://www.wikidata.org/entity/Q38407471

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

@en

type

Item

label

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

@en

prefLabel

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

@en

P1476

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

@en

P2093

Amadeo M Parissenti

http://www.w3.org/2001/XMLSchema#string

Baoqing Guo

http://www.w3.org/2001/XMLSchema#string

Kenneth P H Pritzker

http://www.w3.org/2001/XMLSchema#string

Laura B Pritzker

http://www.w3.org/2001/XMLSchema#string

Lois E Shepherd

http://www.w3.org/2001/XMLSchema#string

Maureen E Trudeau

http://www.w3.org/2001/XMLSchema#string

Xiaohui Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The RIN: an RNA integrity number for assigning integrity values to RNA measurements

Cardioprotective interventions for cancer patients receiving anthracyclines

Primary systemic chemotherapy for inflammatory breast cancer.

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Quantitative assessment of tumor metabolism using FDG-PET imaging.

Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review

Neoadjuvant chemotherapy for operable breast cancer.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

P2888

s10549-015-3498-9

P304

135-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-015-3498-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P50

Mu Zhu

P577

2015-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280388427

http://www.w3.org/2001/XMLSchema#string

P6179

1038211180

http://www.w3.org/2001/XMLSchema#string

P698

26208483

http://www.w3.org/2001/XMLSchema#string

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

about

P2860

P2860

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698